HER-2 amplification impedes the antiproliferative effects of hormone therapy in estrogen receptor-positive primary breast cancer.

In experimental models, human epidermal growth factor receptor-2 (HER-2) amplification leads to estrogen independence and tamoxifen resistance in estrogen receptor (ER)-positive human breast cancer cells. Some but not all reports suggest an association between HER-2 positivity and hormone independence in breast cancer patients. This study aimed to evaluate the antiproliferative effects of endocrine therapy in HER-2-positive/ER-positive primary human breast cancer. The effect on proliferation (Ki67) of hormone therapy was assessed at 2 weeks and/or 12 weeks in biopsies from 115 primary breast cancers with ER-positive tumors. The patients took part in one of 3 neoadjuvant trials of hormonal therapy with a SERM (tamoxifen or idoxifene) or an aromatase inhibitor (anastrozole or vorozole). HER-2 status was assessed by immunocytochemistry and fluorescence in situ hybridization (FISH). Fifteen patients were defined as HER-2 positive by both immunohistochemistry and FISH, with the remaining 100 patients HER-2 negative. Geometric mean Ki67 levels were substantially higher in HER-2-positive than HER-2-negative tumors (27.7% versus 11.5%, respectively; P = 0.003). In HER-2-negative patients, Ki67 was reduced by 62 and 71% at 2 and 12 weeks, respectively (P < 0.0001 for both), but HER-2-positive patients showed no significant fall. The proportional change in Ki67 was significantly different between HER-2-positive and -negative patients (P = 0.014 at 2 weeks; P = 0.047 at 12 weeks). Mean ER levels were lower in the HER-2-positive patients (P = 0.06) but the change in Ki67 was impeded even in those with high ER. Apoptotic index was reduced by 30% at 2 weeks in the HER-2-negative group. However, there were no statistically significant differences in apoptotic index between the groups. It is concluded that ER-positive/HER-2-positive primary breast carcinomas show an impeded antiproliferative response to endocrine therapy that nonetheless may vary between individual treatments. This together with high baseline proliferation is likely to translate to poor clinical response.

[1]  M. Dowsett,et al.  Comparison of the systemic and intratumoral effects of tamoxifen and the aromatase inhibitor vorozole in postmenopausal patients with primary breast cancer. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  A. Lenferink,et al.  Inhibition of HER2/neu (erbB-2) and mitogen-activated protein kinases enhances tamoxifen action against HER2-overexpressing, tamoxifen-resistant breast cancer cells. , 2000, Cancer research.

[3]  M. Dowsett,et al.  Antiproliferative effects of idoxifene in a placebo-controlled trial in primary human breast cancer. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[4]  C. Lange,et al.  Phosphorylation of human progesterone receptors at serine-294 by mitogen-activated protein kinase signals their degradation by the 26S proteasome. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[5]  T. Powles,et al.  Prediction of clinical outcome from primary tamoxifen by expression of biologic markers in breast cancer patients. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[6]  D. McDonnell,et al.  The Molecular Pharmacology of SERMs , 1999, Trends in Endocrinology & Metabolism.

[7]  C. Hudis,et al.  Phase II study of weekly intravenous trastuzumab (Herceptin) in patients with HER2/neu-overexpressing metastatic breast cancer. , 1999, Seminars in oncology.

[8]  M. Dowsett,et al.  Idoxifene antagonizes estradiol-dependent MCF-7 breast cancer xenograft growth through sustained induction of apoptosis. , 1999, Cancer research.

[9]  M. Baum.  Use of aromatase inhibitors in the adjuvant treatment of breast cancer. , 1999, Endocrine-related cancer.

[10]  F. Révillion,et al.  ERBB2 oncogene in human breast cancer and its clinical significance. , 1998, European journal of cancer.

[11]  F. Perrone,et al.  P46 15 year update of the naples GUN trial of adjuvant breast cancer therapy: Evidence of interaction between c-erb-B2 expression and Tamoxifen efficacy , 1998 .

[12]  Y. Yarden,et al.  Differential expression of NDF/neuregulin receptors ErbB-3 and ErbB-4 and involvement in inhibition of neuronal differentiation , 1997, Oncogene.

[13]  B. Angus,et al.  New monoclonal antibodies to oestrogen and progesterone receptors effective for paraffin section immunohistochemistry , 1997, The Journal of pathology.

[14]  M. Dowsett,et al.  Expression of epidermal growth factor receptor and c-erbB2 during the development of tamoxifen resistance in human breast cancer. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

[15]  N. Hynes,et al.  The biology of erbB-2/neu/HER-2 and its role in cancer. , 1994, Biochimica et biophysica acta.

[16]  D. Slamon,et al.  Sensitivity of HER-2/neu antibodies in archival tissue samples: potential source of error in immunohistochemical studies of oncogene expression. , 1994, Cancer research.

[17]  D. Slamon,et al.  Transformation mediated by the human HER-2 gene independent of the epidermal growth factor receptor. , 1992, Oncogene.

[18]  J. Cairns,et al.  Relationship between c-erbB-2 protein product expression and response to endocrine therapy in advanced breast cancer. , 1992, British Journal of Cancer.

[19]  J. Milner,et al.  A Hitchhiker’s Guide to the NIEHS Strategic Plan , 1990, British Journal of Cancer.

[20]  W Godolphin,et al.  Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. , 1989, Science.

[21]  E. Jensen,et al.  Estrophilin assays in breast cancer: Quantitative features and application to the mastectomy specimen , 1980, Cancer.

[22]  M. Dowsett.  Aromatase inhibition: the outcome of twenty years of drug development , 2001 .

[23]  S. Martino,et al.  HER-2 expression and response to tamoxifen in estrogen receptor-positive breast cancer: a Southwest Oncology Group Study. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.